Publication
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (6)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 6
- cancerMalignant Pancreatic Neoplasmcivic_curation1.00
- drugOlaparibcivic_curation1.00
- geneBRCA1civic_curation1.00
- geneBRCA2civic_curation1.00
- variantBRCA1 Mutationcivic_curation1.00
- variantBRCA2 Mutationcivic_curation1.00
Curated evidence
Evidence citing this paper (4)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 25366685
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| BRCA1 Loss-of-function1 | ||||||||
| Olaparib | Malignant Pancreatic Neoplasm | Predictive | B | Supports Sensitivity Response | 3 | rejected | EID6075In multicenter phase II study included individuals with a germline BRCA1/2 mutation and pancreatic cancer after gemcitabine treatment. Olaparib was administered at 400 mg twice per day. Tumor respons… (full text at CIViC) PMID 25366685 · Kaufman et al., 2015 · Open in CIViC | civic |
| BRCA1 Mutation1 | ||||||||
| Olaparib | Malignant Pancreatic Neoplasm | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID5914Twenty-three patients with pancreatic cancer havoring BRCA1/2 germline mutations received olaparib. Five (21.7%) patients had a BRCA1 mutation. All but one had received prior gemcitabine, and 65% had … (full text at CIViC) PMID 25366685 · Kaufman et al., 2015 · Open in CIViC | civic |
| BRCA2 Loss-of-function1 | ||||||||
| Olaparib | Malignant Pancreatic Neoplasm | Predictive | B | Supports Sensitivity Response | 3 | rejected | EID6076A multicenter phase II study included pancreatic cancer patients with a germline BRCA1/2 mutation after gemcitabine treatment. Olaparib was administered at 400 mg twice per day. Tumor response rate wa… (full text at CIViC) PMID 25366685 · Kaufman et al., 2015 · Open in CIViC | civic |
| BRCA2 Mutation1 | ||||||||
| Olaparib | Malignant Pancreatic Neoplasm | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID5913Twenty-three patients with pancreatic cancer havoring BRCA1/2 germline mutations received olaparib. Eighteen (78%) patients had a BRCA2 mutation. In total of patients with BRCA1/2 mutation , all but … (full text at CIViC) PMID 25366685 · Kaufman et al., 2015 · Open in CIViC | civic |